ArticleNeoplasia (New York, N.Y.)2014
Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome.
Article in Neoplasia (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 65 citations in OpenAlex.
- Double faces of pheochromocytoma and paraganglioma-a review of integrated pathologic diagnosis.Endocrine journal · 2026Review
- The International Collaborative Animal Study of the carcinogenicity and genotoxicity of mobile phone radiofrequency radiation: the Korean study.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Coexistence of primary aldosteronism and micro-pheochromocytoma: a case report with pathological analysis and literature review.Frontiers in medicine · 2026Article
- MEN2: surgical precision in the era of precision medicine.Endocrine-related cancer · 2025Review
- A Cortisol-Secreting Adrenal Adenoma Combined With a Micro-Pheochromocytoma: Case Report and Literature Review.Clinical medicine insights. Endocrinology and diabetes · 2023Article
- Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.Endocrine pathology · 2022Review
- Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting.Human pathology · 2021Review
- MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.Endocrine · 2020Review
- A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats.Endocrine-related cancer · 2020Article
- 100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A.Endocrine · 2020Article
- Isolated left adrenal medullary hyperplasia.Journal of cardiology cases · 2020Article
- Presentation, Treatment, Histology, and Outcomes in Adrenal Medullary Hyperplasia Compared With Pheochromocytoma.Journal of the Endocrine Society · 2019Article
- Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin.Cancers · 2019Review
- A Case of Juvenile Hypertension Suggestive of Adrenomedullary Hyperplasia.Internal medicine (Tokyo, Japan) · 2019Article
- Pheochromocytoma arising from an ectopic adrenal tissue in multiple endocrine neoplasia type 2A.Endocrinology, diabetes & metabolism case reports · 2019Article
- The RET C611Y mutation causes MEN 2A and associated cutaneousEndocrine connections · 2018Article
- Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation.Endocrine pathology · 2017Article
- Frequency of Cushing's syndrome due to ACTH-secreting adrenal medullary lesions: a retrospective study over 10 years from a single center.Endocrine · 2017Article
- Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.Journal of internal medicine · 2016Review
- Multiple Endocrine Neoplasia: A Genetically Diverse Group of Familial Tumor Syndromes.Journal of pediatric genetics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenal medullary hyperplasias (AMHs) are adrenal medullary proliferations with a size < 1 cm, while larger lesions are considered as pheochromocytoma (PCC). This arbitrary distinction has been proposed decades ago, although the biological relationship between AMH and PCC has never been investigated. Both lesions are frequently diagnosed in multiple endocrine neoplasia type 2 (MEN2) patients in whom they are considered as two unrelated clinical entities. In this study, we investigated the molecular relationship between AMH and PCC in MEN2 patients. Molecular aberrations of 19 AMHs and 13 PCCs from 18 MEN2 patients were determined by rearranged during transfection (RET) proto-oncogene mutation analysis and loss of heterozygosity (LOH) analysis for chromosomal regions 1p13, 1p36, 3p, and 3q, genomic areas covering commonly altered regions in RET-related PCC. Identical molecular aberrations were found in all AMHs and PCCs, at similar frequencies. LOH was seen for chromosomes 1p13 in 8 of 18 (44%), 1p36 in 9 of 15 (60%), 3p12-13 in 12 of 18 (67%), and 3q23-24 in 10 of 16 (63%) of AMHs, and for chromosome 1p13 in 13 of 13 (100%), 1p36 in 7 of 11 (64%), 3p12-13 in 4 of 11 (36%), and 3q23-24 in 11 of 12 (92%) of PCCs. Our results indicate that AMHs are not hyperplasias and, in clinical practice, should be regarded as PCCs, which has an impact on diagnosis and treatment of MEN2 patients. We therefore propose to replace the term AMH by micro-PCC to indicate adrenal medullary proliferations of less than 1 cm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.